These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38959712)

  • 1. Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial.
    Downs J; Jacoby P; Specchio N; Cross H; Amin S; Bahi-Buisson N; Rajaraman R; Suter B; Devinsky O; Aimetti A; Busse G; Olson HE; Demarest S; Benke TA; Pestana-Knight E
    Eur J Paediatr Neurol; 2024 Jul; 51():140-146. PubMed ID: 38959712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
    Knight EMP; Amin S; Bahi-Buisson N; Benke TA; Cross JH; Demarest ST; Olson HE; Specchio N; Fleming TR; Aimetti AA; Gasior M; Devinsky O;
    Lancet Neurol; 2022 May; 21(5):417-427. PubMed ID: 35429480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.
    Olson HE; Amin S; Bahi-Buisson N; Devinsky O; Marsh ED; Pestana-Knight E; Rajaraman RR; Aimetti AA; Rybak E; Kong F; Miller I; Hulihan J; Demarest S
    Epilepsia; 2024 Jan; 65(1):37-45. PubMed ID: 37950390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.
    Sperling MR; Klein P; Tsai J
    Epilepsia; 2017 Apr; 58(4):558-564. PubMed ID: 28230252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy.
    Sullivan J; Gunning B; Zafar M; Guerrini R; Gecz J; Kolc KL; Zhao Y; Gasior M; Aimetti AA; Samanta D
    Epilepsy Res; 2023 Mar; 191():107112. PubMed ID: 36870093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganaxolone: First Approval.
    Lamb YN
    Drugs; 2022 Jun; 82(8):933-940. PubMed ID: 35596878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database.
    Wong K; Junaid M; Alexander S; Olson HE; Pestana-Knight EM; Rajaraman RR; Downs J; Leonard H
    CNS Drugs; 2024 Sep; 38(9):719-732. PubMed ID: 39060900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
    Leonard H; Junaid M; Wong K; Demarest S; Downs J
    Epilepsy Res; 2021 Jan; 169():106521. PubMed ID: 33341033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
    Devinsky O; King L; Bluvstein J; Friedman D
    Ann Clin Transl Neurol; 2021 Mar; 8(3):639-644. PubMed ID: 33538404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences on the trajectory and subsequent outcomes in CDKL5 deficiency disorder.
    Leonard H; Junaid M; Wong K; Aimetti AA; Pestana Knight E; Downs J
    Epilepsia; 2022 Feb; 63(2):352-363. PubMed ID: 34837650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.
    Gould A; Amin S
    Expert Rev Neurother; 2024 Oct; 24(10):945-951. PubMed ID: 39082513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
    Demarest ST; Olson HE; Moss A; Pestana-Knight E; Zhang X; Parikh S; Swanson LC; Riley KD; Bazin GA; Angione K; Niestroj LM; Lal D; Juarez-Colunga E; Benke TA
    Epilepsia; 2019 Aug; 60(8):1733-1742. PubMed ID: 31313283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE).
    Demarest S; Jeste S; Agarwal N; Arkilo D; Asgharnejad M; Hsiao S; Thibert R
    Epilepsy Behav; 2023 May; 142():109173. PubMed ID: 37011526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of ganaxolone in posttraumatic stress disorder.
    Rasmusson AM; Marx CE; Jain S; Farfel GM; Tsai J; Sun X; Geracioti TD; Hamner MB; Lohr J; Rosse R; Summerall L; Naylor JC; Cusin C; Lang AJ; Raman R; Stein MB
    Psychopharmacology (Berl); 2017 Aug; 234(15):2245-2257. PubMed ID: 28667510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
    Lim Z; Wong K; Downs J; Bebbington K; Demarest S; Leonard H
    Epilepsy Res; 2018 Oct; 146():36-40. PubMed ID: 30071384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy.
    Khan P; Saini S; Hussain S; Majid H; Gupta S; Agarwal N
    Expert Opin Pharmacother; 2024 Apr; 25(5):621-632. PubMed ID: 38606458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
    Devinsky O; King L; Schwartz D; Conway E; Price D
    Epilepsia; 2021 Jul; 62(7):e98-e102. PubMed ID: 33979451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
    Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
    Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
    Devinsky O; Verducci C; Thiele EA; Laux LC; Patel AD; Filloux F; Szaflarski JP; Wilfong A; Clark GD; Park YD; Seltzer LE; Bebin EM; Flamini R; Wechsler RT; Friedman D
    Epilepsy Behav; 2018 Sep; 86():131-137. PubMed ID: 30006259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder.
    Tangarorang J; Leonard H; Epstein A; Downs J
    Am J Med Genet A; 2019 Feb; 179(2):249-256. PubMed ID: 30561084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.